Faculty of Engineering and Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, UK.
Pharmaceutical Research, Division of Medical Sciences, Department of Health Science, Luleå University of Technology, Luleå, SE -97187, Sweden.
Adv Drug Deliv Rev. 2017 Aug 1;117:162-177. doi: 10.1016/j.addr.2017.08.006. Epub 2017 Aug 12.
Cocrystals are crystalline single phase materials composed of two or more different molecular and/or ionic compounds generally in a stoichiometric ratio which are neither solvates nor simple salts. If one of the components is an active pharmaceutical ingredient (API), the term pharmaceutical cocrystal is often used. There is a growing interest among drug development scientists in exploring cocrystals, as means to address physicochemical, biopharmaceutical and mechanical properties and expand solid form diversity of the API. Conventionally, coformers are selected based on crystal engineering principles, and the equimolar mixtures of API and coformers are subjected to solution-based crystallization that are commonly employed in polymorph and salt screening. However, the availability of new knowledge on cocrystal phase behaviour in solid state and solutions has spurred the development and implementation of more rational experimental cocrystal screening as well as scale-up methods. This review aims to provide overview of commonly employed solid form screening techniques in drug development with an emphasis on cocrystal screening methodologies. The latest developments in understanding and the use of cocrystal phase diagrams in both screening and solution based scale-up methods are also presented. Final section is devoted to reviewing the state of the art research covering solution based scale-up cocrystallization process for different cocrystals besides more recent continuous crystallization methods.
共晶是由两种或两种以上不同的分子和/或离子化合物组成的单相晶体材料,通常以化学计量比存在,既不是溶剂化物也不是简单的盐。如果其中一种成分是活性药物成分(API),则通常使用药物共晶这个术语。药物开发科学家对探索共晶越来越感兴趣,因为这是一种解决 API 的物理化学、生物制药和机械性能并扩大其固体形式多样性的方法。传统上,共晶形成剂是根据晶体工程原理选择的,API 和共晶形成剂的等摩尔混合物经过基于溶液的结晶,通常用于多晶型和盐筛选。然而,共晶相在固态和溶液中行为的新知识的出现,推动了更合理的实验性共晶筛选以及放大方法的发展和实施。本综述旨在提供药物开发中常用的固体形式筛选技术概述,重点介绍共晶筛选方法。还介绍了共晶相图在筛选和基于溶液的放大方法中的最新理解和应用的最新进展。最后一部分专门讨论了涵盖不同共晶的基于溶液的放大共晶化过程的最新研究现状,以及最近的连续结晶方法。